US › Healthcare

Akebia Ther (AKBA)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$0.90-2.43%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$49.1M

Revenue YoY

-21.4%

Net profit

$-8.9M

Profit YoY

-3706.5%

EPS

$-0.02

EPS estimate

$-0.03

Net margin

-18.1%

EPS came in at -0.02 against a street estimate of -0.03 — a beat of 33.3%.

Key statistics

Market cap

$263.7M

Forward P/E

28.7

P/B

10.54

Book value

$0.09

EPS (TTM)

$-0.12

52-week high

$3.20

52-week low

$0.81

50-day MA

$1.11

200-day MA

$1.28

Beta

0.19

Analyst view

Analysts rate Akebia Ther a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $3.80.

Shareholding

Insiders

4.06%

Institutions

42.98%

Largest institutional holders

Fund	Stake
BlackRock Inc	6.75%
State Street Corp	4.19%
Vanguard Capital Management, LLC	4.03%
Geode Capital Management, LLC	2.33%
The Goldman Sachs Group Inc	1.30%
Millennium Management LLC	1.15%
Citigroup Inc	1.03%
Bank of America Corp	1.00%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Akebia Ther — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.